Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2024
Same author

Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.

The Lancet. Neurology·2024
Same author

MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same author

Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.

Annals of neurology·2023
Same author

Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.

Multiple sclerosis (Houndmills, Basingstoke, England)·2023

Related Experiment Video

Updated: May 20, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Neuromyelitis optica spectrum disorders.

Dean M Wingerchuk

    Continuum (Minneapolis, Minn.)
    |July 20, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Neuromyelitis optica is an inflammatory CNS disorder distinct from MS. Aquaporin-4 autoantibodies are key biomarkers, guiding current treatments and future research into its unique immunopathology.

    More Related Videos

    Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
    09:29

    Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

    Published on: August 21, 2017

    Related Experiment Videos

    Last Updated: May 20, 2026

    Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
    12:23

    Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

    Published on: April 14, 2014

    Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
    09:29

    Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

    Published on: August 21, 2017

    Area of Science:

    • Central Nervous System (CNS) inflammatory demyelinating disorders.
    • Neuroimmunology and autoimmune diseases.
    • Clinical neurology and diagnostics.

    Background:

    • Neuromyelitis optica (NMO) is a rare CNS inflammatory demyelinating disease.
    • NMO exhibits distinct clinical, laboratory, neuroimaging, and prognostic features compared to multiple sclerosis (MS).
    • The discovery of aquaporin-4 (AQP4) autoantibodies has been pivotal in defining NMO spectrum disorders.

    Purpose of the Study:

    • To differentiate Neuromyelitis Optica (NMO) from Multiple Sclerosis (MS).
    • To highlight the diagnostic significance of aquaporin-4 autoantibodies in NMO.
    • To review current and future therapeutic strategies for NMO.

    Main Methods:

    • Review of clinical, laboratory, neuroimaging, and prognostic data.
    • Analysis of the role of aquaporin-4 autoantibodies in NMO pathogenesis.
    • Evaluation of existing treatment strategies, including corticosteroids, plasmapheresis, and immunosuppression.

    Main Results:

    • Aquaporin-4 autoantibodies are highly specific biomarkers for NMO spectrum disorders.
    • Evidence supports the pathogenic role of AQP4 autoantibodies in the vasculocentric immunopathology of NMO.
    • Current treatments focus on managing acute attacks and preventing future relapses.

    Conclusions:

    • Neuromyelitis optica is a distinct CNS disorder characterized by AQP4 autoimmunity.
    • Targeting AQP4 and understanding its pathogenic mechanisms are crucial for effective NMO management.
    • Ongoing research, including animal models, aims to refine treatment strategies based on disease mechanisms.